Locoregional Recurrence Risk in Breast Cancer Patients with Estrogen Receptor Positive Tumors and Residual Nodal Disease following Neoadjuvant Chemotherapy and Mastectomy without Radiation Therapy

Table 1

Patient and tumor characteristics ().

Characteristic	(%)
Age at diagnosis
Median (range)	48 yrs (31–87 yrs)
Biopsy grade
1	11 (13%)
2	27 (31%)
3	41 (47%)
Unknown	8 (9%)
Estrogen receptor status
Positive	55 (63%)
Negative	32 (37%)
Progesterone receptor status
Positive	40 (46%)
Negative	45 (52%)
Unknown	2 (2%)
Her2+ receptor status
Positive	23 (26%)
Negative	59 (68%)
Unknown	5 (6%)
Triple negative receptor status	23 (26%)
ypT stage
T0	7 (8%)
Tis	11 (13%)
T1mi/T1	44 (51%)
T2	20 (23%)
T3/T4	4 (4%)
Unknown	1 (1%)
ypN stage
N0/0(i+)	52 (60%)
N+	35 (40%)
N1mi	3
N1a	25
N2a	6
N3a	1
LVI
Yes	18 (21%)
No	67 (77%)
Unknown	2 (2%)
Close or positive margins
Yes	12 (14%)
No	75 (86%)
Extranodal extension
Yes	4 (5%)
No	82 (94%)
Unknown	1 (1%)
Lymph node ratio
0%	52 (60%)
0–20%	23 (26%)
>20%	12 (14%)

yrs, years; LVI, lymphovascular invasion.